Affinity Asset Advisors
Latest statistics and disclosures from Affinity Asset Advisors's latest quarterly 13F-HR filing:
- Top 5 stock holdings are SPY, APGE, XENE, ERAS, INSM, and represent 25.86% of Affinity Asset Advisors's stock portfolio.
- Added to shares of these 10 stocks: SPY (+$130M), MRNA (+$41M), Centessa Pharmaceuticals (+$32M), ROIV (+$31M), ANAB (+$28M), XENE (+$25M), DNTH (+$24M), ERAS (+$24M), ELVN (+$23M), BMY (+$18M).
- Started 26 new stock positions in NVO, GENB, EQ, BMY, HLXC, ALEC, KRRO, SGP, ANL, MRNA.
- Reduced shares in these 10 stocks: , IBB (-$68M), VTYX (-$59M), AMGN (-$48M), , ACLX (-$19M), CGEM (-$16M), ORKA (-$15M), BBIO (-$13M), ABVX (-$11M).
- Sold out of its positions in AMGN, ABUS, RCUS, GERN, IBB, MRSN, XBI, XLV, SMMT, TNGX. Travere Therapeutics, RARE, VTYX, AVDL, PCSC.
- Affinity Asset Advisors was a net buyer of stock by $69M.
- Affinity Asset Advisors has $1.9B in assets under management (AUM), dropping by 10.33%.
- Central Index Key (CIK): 0001773195
Tip: Access up to 7 years of quarterly data
Positions held by Affinity Asset Advisors consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Affinity Asset Advisors
Affinity Asset Advisors holds 103 positions in its portfolio as reported in the March 2026 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| State Str Spdr S&p 500 Etf T Tr Unit Put Option (SPY) | 6.7 | $130M | NEW | 200k | 650.34 |
|
| Apogee Therapeutics (APGE) | 5.6 | $108M | +4% | 1.3M | 84.17 |
|
| Xenon Pharmaceuticals (XENE) | 5.0 | $97M | +34% | 1.7M | 58.15 |
|
| Erasca (ERAS) | 4.5 | $87M | +37% | 5.4M | 16.18 |
|
| Insmed Com Par $.01 (INSM) | 4.1 | $79M | +6% | 480k | 163.52 |
|
| Roivant Sciences SHS (ROIV) | 4.0 | $78M | +64% | 2.8M | 27.70 |
|
| Spyre Therapeutics Com New (SYRE) | 3.3 | $65M | -10% | 1.3M | 50.44 |
|
| Centessa Pharmaceuticals Sponsored Ads | 2.9 | $56M | +133% | 1.4M | 39.72 |
|
| Praxis Precision Medicines I Com New (PRAX) | 2.8 | $55M | -8% | 170k | 322.19 |
|
| Anaptysbio Inc Common (ANAB) | 2.7 | $52M | +111% | 940k | 55.46 |
|
| Alkermes SHS (ALKS) | 2.5 | $48M | +35% | 1.4M | 35.36 |
|
| Cytokinetics Com New (CYTK) | 2.4 | $46M | -12% | 701k | 65.91 |
|
| Abivax Sa Sponsored Ads (ABVX) | 2.3 | $45M | -19% | 405k | 111.35 |
|
| Teva Pharmaceutical Inds Sponsored Ads (TEVA) | 2.2 | $42M | 1.4M | 30.12 |
|
|
| Arcellx Common Stock (ACLX) | 2.2 | $42M | -30% | 363k | 114.82 |
|
| Moderna Call Option (MRNA) | 2.1 | $41M | NEW | 800k | 50.80 |
|
| Dianthus Therapeutics (DNTH) | 1.7 | $34M | +247% | 400k | 83.92 |
|
| Nuvalent Inc-a (NUVL) | 1.6 | $31M | -7% | 300k | 102.45 |
|
| Terns Pharmaceuticals (TERN) | 1.5 | $30M | +2% | 563k | 52.72 |
|
| Lexeo Therapeutics (LXEO) | 1.5 | $29M | +57% | 5.1M | 5.74 |
|
| Cogent Biosciences (COGT) | 1.5 | $29M | +114% | 750k | 38.49 |
|
| Madrigal Pharmaceuticals (MDGL) | 1.5 | $29M | +76% | 55k | 523.47 |
|
| Sutro Biopharma Com Shs (STRO) | 1.4 | $27M | +42% | 1.1M | 24.91 |
|
| Forte Biosciences Com New (FBRX) | 1.4 | $26M | 1.0M | 25.90 |
|
|
| Oruka Therapeutics (ORKA) | 1.3 | $25M | -37% | 500k | 49.05 |
|
| Trevi Therapeutics (TRVI) | 1.2 | $24M | -6% | 2.0M | 11.93 |
|
| Ovid Therapeutics (OVID) | 1.2 | $24M | +48% | 11M | 2.22 |
|
| Enliven Therapeutics (ELVN) | 1.2 | $23M | NEW | 587k | 39.20 |
|
| Ascendis Pharma A/s Sponsored Adr | 1.1 | $22M | +216% | 95k | 228.73 |
|
| Mineralys Therapeutics (MLYS) | 1.0 | $20M | +2% | 750k | 27.09 |
|
| Avalo Therapeutics Com New (AVTX) | 1.0 | $20M | +27% | 1.3M | 14.93 |
|
| Revolution Medicines (RVMD) | 1.0 | $20M | +100% | 200k | 97.25 |
|
| Bristol Myers Squibb Call Option (BMY) | 0.9 | $18M | NEW | 300k | 60.65 |
|
| Protagonist Therapeutics (PTGX) | 0.9 | $18M | 172k | 105.40 |
|
|
| Celldex Therapeutics Com New (CLDX) | 0.8 | $16M | +42% | 500k | 31.72 |
|
| Zura Bio Class A Ord Shs (ZURA) | 0.8 | $15M | +41% | 2.6M | 5.95 |
|
| Nurix Therapeutics (NRIX) | 0.8 | $15M | 968k | 15.50 |
|
|
| Savara (SVRA) | 0.7 | $14M | -10% | 2.5M | 5.46 |
|
| Omeros Corp Note 9.500% 6/1 (Principal) | 0.7 | $13M | 6.5M | 2.03 |
|
|
| Perspective Therapeutics Com New (CATX) | 0.7 | $13M | +954% | 3.2M | 4.17 |
|
| Helix Acquisition Corp Iii Usd Cl A Ord Shs (HLXC) | 0.7 | $13M | NEW | 1.3M | 10.16 |
|
| Arrowhead Pharmaceuticals (ARWR) | 0.6 | $13M | +185% | 200k | 62.70 |
|
| Damora Therapeutics Com New (DMRA) | 0.6 | $12M | NEW | 450k | 25.90 |
|
| Eupraxia Pharmaceuticals (EPRX) | 0.6 | $12M | +429% | 1.6M | 7.24 |
|
| Alto Neuroscience Com Shs (ANRO) | 0.6 | $11M | NEW | 500k | 22.48 |
|
| Bridgebio Pharma (BBIO) | 0.6 | $11M | -53% | 150k | 74.26 |
|
| Cullinan Oncology (CGEM) | 0.6 | $11M | -59% | 781k | 14.21 |
|
| Belite Bio Sponsored Ads (BLTE) | 0.5 | $10M | +225% | 65k | 159.44 |
|
| Wave Life Sciences SHS (WVE) | 0.5 | $10M | -48% | 1.4M | 7.25 |
|
| Vera Therapeutics Cl A (VERA) | 0.5 | $10M | 250k | 40.23 |
|
|
| Tyra Biosciences (TYRA) | 0.5 | $9.9M | NEW | 258k | 38.30 |
|
| Immunitybio Put Option (IBRX) | 0.5 | $9.6M | NEW | 1.3M | 7.67 |
|
| Jade Biosciences Com New (JBIO) | 0.5 | $9.0M | -10% | 640k | 14.05 |
|
| Travere Therapeutics (TVTX) | 0.5 | $8.9M | 300k | 29.71 |
|
|
| Newamsterdam Pharma Company Ordinary Shares (NAMS) | 0.5 | $8.8M | 275k | 32.01 |
|
|
| Cogent Biosciences Note 1.625%11/1 (Principal) | 0.4 | $8.6M | +600% | 7.0M | 1.23 |
|
| Korro Bio (KRRO) | 0.4 | $8.0M | NEW | 707k | 11.32 |
|
| Celcuity Note 2.750% 8/0 (Principal) | 0.4 | $7.3M | 3.0M | 2.44 |
|
|
| Crispr Therapeutics Namen Akt (CRSP) | 0.4 | $7.1M | NEW | 150k | 47.57 |
|
| Spyglass Pharma Com Shs (SGP) | 0.3 | $6.5M | NEW | 250k | 25.91 |
|
| Novo-nordisk A S Adr Call Option (NVO) | 0.3 | $6.4M | NEW | 175k | 36.75 |
|
| Compass Pathways Sponsored Ads (CMPS) | 0.3 | $6.1M | +454% | 1.1M | 5.53 |
|
| Ibio Com New (IBIO) | 0.3 | $5.9M | +51% | 3.1M | 1.90 |
|
| Establishment Labs Holdings Ord (ESTA) | 0.3 | $5.7M | -50% | 100k | 56.78 |
|
| Anteris Technologies Global (AVR) | 0.3 | $5.1M | +87% | 912k | 5.55 |
|
| Newamsterdam Pharma Company *w Exp 99/99/999 (NAMSW) | 0.3 | $4.9M | 245k | 20.04 |
|
|
| Uniqure Nv SHS Call Option (QURE) | 0.3 | $4.9M | -64% | 300k | 16.35 |
|
| Miragen Therapeutics (VRDN) | 0.3 | $4.9M | 250k | 19.56 |
|
|
| Eliem Therapeutics (CLYM) | 0.2 | $4.8M | -46% | 700k | 6.85 |
|
| Rezolute Com New (RZLT) | 0.2 | $4.7M | -34% | 1.5M | 3.05 |
|
| Sagimet Biosciences Com Ser A (SGMT) | 0.2 | $4.5M | -24% | 868k | 5.22 |
|
| Mbx Biosciences (MBX) | 0.2 | $4.5M | -40% | 150k | 29.85 |
|
| Taysha Gene Therapies Com Shs (TSHA) | 0.2 | $4.5M | -69% | 1.0M | 4.47 |
|
| Veradermics Common Stock (MANE) | 0.2 | $4.4M | NEW | 70k | 63.15 |
|
| Generate Biomedicines Com Shs (GENB) | 0.2 | $4.4M | NEW | 350k | 12.50 |
|
| Engene Holdings | 0.2 | $4.2M | -5% | 610k | 6.81 |
|
| Cg Oncology Call Option (CGON) | 0.2 | $4.1M | NEW | 60k | 67.68 |
|
| Arrivent Biopharma (AVBP) | 0.2 | $4.0M | +16% | 175k | 23.07 |
|
| Relay Therapeutics (RLAY) | 0.2 | $4.0M | NEW | 400k | 9.95 |
|
| Proqr Thrapeutics N V Shs Euro (PRQR) | 0.2 | $4.0M | 2.5M | 1.62 |
|
|
| Verrica Pharmaceuticals Com Shs (VRCA) | 0.2 | $3.7M | 707k | 5.29 |
|
|
| Celcuity Call Option (CELC) | 0.2 | $3.4M | NEW | 30k | 114.14 |
|
| Precision Biosciences Com New (DTIL) | 0.2 | $3.3M | NEW | 598k | 5.50 |
|
| Karyopharm Therapeutics Com New (KPTI) | 0.1 | $2.8M | -43% | 500k | 5.57 |
|
| Sol-gel Technologies Shs New (SLGL) | 0.1 | $2.8M | NEW | 35k | 79.22 |
|
| Crinetics Pharmaceuticals In (CRNX) | 0.1 | $2.7M | 75k | 36.32 |
|
|
| Oaktree Acquisition Corp Iii Unit 10/04/2029 (OACCU) | 0.1 | $2.7M | 250k | 10.65 |
|
|
| Nextcure Com New (NXTC) | 0.1 | $2.6M | -2% | 242k | 10.68 |
|
| Immunovant (IMVT) | 0.1 | $2.5M | -50% | 100k | 24.84 |
|
| Equillium (EQ) | 0.1 | $2.5M | NEW | 1.2M | 2.00 |
|
| Sab Biotherapeutics Com New (SABS) | 0.1 | $2.2M | NEW | 575k | 3.83 |
|
| Corcept Therapeutics Incorporated (CORT) | 0.1 | $2.0M | NEW | 50k | 40.31 |
|
| Health Sciences Acq Corp 2 (OBIO) | 0.1 | $1.7M | -29% | 403k | 4.25 |
|
| Kezar Life Sciences Com New | 0.1 | $1.7M | 229k | 7.42 |
|
|
| Macrogenics (MGNX) | 0.1 | $1.4M | +3% | 500k | 2.89 |
|
| Adlai Nortye Sponsored Ads (ANL) | 0.1 | $1.1M | NEW | 165k | 6.92 |
|
| Alector (ALEC) | 0.1 | $1.1M | NEW | 500k | 2.15 |
|
| Onkure Therapeutics Com Cl A (OKUR) | 0.1 | $998k | NEW | 241k | 4.14 |
|
| Lenz Therapeutics (LENZ) | 0.0 | $915k | 100k | 9.15 |
|
|
| X4 Pharmaceuticals Com New (XFOR) | 0.0 | $599k | 145k | 4.13 |
|
|
| Q32 Bio (QTTB) | 0.0 | $178k | 28k | 6.42 |
|
|
| Adagio Med Hldgs (ADGM) | 0.0 | $92k | 80k | 1.15 |
|
|
| Rocket Pharmaceuticals *w Exp 09/02/202 (RCKTW) | 0.0 | $1.2k | 75k | 0.02 |
|
Past Filings by Affinity Asset Advisors
SEC 13F filings are viewable for Affinity Asset Advisors going back to 2020
- Affinity Asset Advisors 2026 Q1 filed May 14, 2026
- Affinity Asset Advisors 2025 Q4 filed Feb. 13, 2026
- Affinity Asset Advisors 2025 Q3 filed Nov. 13, 2025
- Affinity Asset Advisors 2025 Q2 filed Aug. 13, 2025
- Affinity Asset Advisors 2025 Q1 filed May 14, 2025
- Affinity Asset Advisors 2024 Q4 filed Feb. 13, 2025
- Affinity Asset Advisors 2024 Q3 filed Nov. 13, 2024
- Affinity Asset Advisors 2024 Q2 filed Aug. 14, 2024
- Affinity Asset Advisors 2024 Q1 filed May 14, 2024
- Affinity Asset Advisors 2023 Q4 filed Feb. 13, 2024
- Affinity Asset Advisors 2023 Q3 filed Nov. 14, 2023
- Affinity Asset Advisors 2023 Q2 restated filed Aug. 21, 2023
- Affinity Asset Advisors 2023 Q2 filed Aug. 14, 2023
- Affinity Asset Advisors 2023 Q1 filed May 15, 2023
- Affinity Asset Advisors 2022 Q4 filed Feb. 13, 2023
- Affinity Asset Advisors 2022 Q3 filed Nov. 14, 2022